Karyopharm shares are trading higher after the company received FDA Fast Track Designation for Selinexor for Myelofibrosis.
Portfolio Pulse from Benzinga Newsdesk
Karyopharm Therapeutics has received FDA Fast Track Designation for its drug Selinexor for Myelofibrosis, leading to a rise in its share prices.
July 18, 2023 | 10:14 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Karyopharm's stock is trading higher following the FDA's Fast Track Designation for Selinexor for Myelofibrosis.
The FDA's Fast Track Designation is a significant regulatory milestone that can expedite the development and review of drugs intended to treat serious conditions and fill unmet medical needs. This news is likely to boost investor confidence in Karyopharm, leading to a short-term increase in its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100